

PERSONAL INFORMATION

Joseph Emmerich

WORK EXPERIENCE

-
- September 1990–October 1991 **Visiting Scientist**
NIH (United States)
Visiting scientist at the National Institute of Health (NIH), Molecular Disease Branch (Pr. Brewer) NHLBI (National Heart Lung and Blood Institute), Bethesda, Maryland, USA).
- November 1991–October 1995 **Fellowship in Cardiology**
University Paris 6 (France)
1991-1995 Chef de Clinique des Universités (Fellowship) – University of Paris 6.
Dept of Vascular Medicine, Broussais University Hospital - University Paris 6.
- November 1995–October 1997 **Senior Lecturer**
Assistance Publique-Hôpitaux de Paris (France)
Senior Lecturer in Internal Medicine. Dept of Vascular Medicine.
- November 1997–May 2012 **Professor of Vascular Medicine**
University Paris Descartes (France)
Professor of Vascular Medicine in Broussais Hospital then Hôpital Européen Georges Pompidou in Paris. From 2010 to 2012 head of the Vascular Medicine Dept.
- January 2006–May 2012 **Head of UMR INSERM laboratory U765, “**
INSERM (France)
Research laboratory : "Thrombosis: epidemiology, physiopathology and innovative therapies".
- May 2012–April 2015 **Director of dept Cardiology, Endocrinology, Gynecology and Urology**
ANSM (Agence Nationale de Sécurité du Médicament et des produits de santé) (France)
- May 2015–Present **Technical advisor**
ANSM (Agence Nationale de Sécurité du Médicament et des produits de santé) (France)
In charge of CHMP for the french medical agency as alternate member
- May 2015–Present **Professor of Vascular Medicine**
University Paris Descartes (France)
Vascular Medicine Dept, Groupe Hospitalier Paris Saint-Joseph, Paris, France

EDUCATION AND TRAINING

-
- November 1985–October 1990 **Residency in Cardiology**
University Paris Cochin (France)
- December 1989– **Board certified in Cardiology**
University Paris Cochin (France)

- December 1990– **Medical Degree**
University Paris Cochin (France)
- September 1987– **Master of Nutrition**
University Paris 7 (France)
Physiology and physiopathology of human nutrition.
- December 1995– **PhD**
University Paris 7 (France)
Hemostasis and Coagulation : "Molecular pathology of serpins and hemostasis anomalies".
- January 2002–January 2010 **Research Professor**
Dept of Pathology (Pr E.G. Bovill), University of Vermont, Burlington (United States)
Research on thrombophilia and participation to grants

ADDITIONAL INFORMATION

Expertise Cardiology, Thrombosis and Haemostasis, Vascular Medicine, Vasculitis, Rare vascular diseases, Molecular biology, Thrombophilia, Contraceptives

- Publications**
1. AUBERT I., EMMERICH J., CHARPAK Y., CHANU B., DACHET D., HERLICH D., BESSEAU M., ROUFFY J., JACOTOT B. Effets de la Simvastatine sur les lipides lipoprotéines et apoprotéines (A1 et B) plasmatiques; 24 cas d'hypercholestérolémie primaire majeure. *Presse Medicale* 1988;17:901-904.
 2. DELPLANQUE B., EMMERICH J., NOROL F., JOURDAN D., DUEDARI N., JACOTOT B. Evaluation des lipides et lipoprotéines sériques dans 3 cas d'hypercholestérolémie familiale hétérozygote traités par aphérese des LDL sur colonne de dextran-cellulose. *Ann Méd Int* 1988;80-82.
 3. BARD J.M., LUC G., DOUSTE-BLAZY P., DROUIN P., ZIEGLER O., JACOTOT B., EMMERICH J., DE GENNES J.L., FRUCHART J.C. Effects of Simvastatin on Lipids, Apolipoproteins, and Lipoprotein particles in Primary Hypercholesterolemia. *Atherosclerosis Reviews*. 1988, Vol. 18, edited by J. Stokes III and M. Mancini. Raven Press, Ltd, New York.
 4. EMMERICH J., THOMAS D., DROBINSKI G., CANNY M., GANDJBAKHCH I., GROSGOGEAT Y. Diagnosis of coronary aneurysms in siblings: Treatment with a new surgical procedure. *Eur Heart J* 1989;10:91-96.
 5. EMMERICH J., AUBERT I., BAUDUCEAU B., DACHET C., CHANU B., ERLICH D., GAUTIER D., JACOTOT B., ROUFFY J. Efficacy and safety of simvastatin (alone or in association with cholestyramine) in a one year study in 66 patients with type II hyperlipoproteinemia. *Eur Heart J* 1990;11:149-155.
 6. GANDRILLE S., VIDAUD D., EMMERICH J., CLAUSER E., SIE P., FIESSINGER J.N., ALHENC-GELAS M., PRIOLLET P., AIACH M. Molecular basis for hereditary antithrombin III quantitative deficiencies: a stop codon in exon IIa and a frameshift in exon VI. *Br J Haematol* 1991;78:414-420.
 7. VIDAUD D., EMMERICH J., SIRIEIX M.E., SIE P., ALHENC-GELAS M., AIACH M. Molecular basis for antithrombin III type I deficiency: Three novel mutations located in exon IV. *Blood* 1991;78:2305-2309.
 8. EMMERICH J., BEG O.U., PETERSON J., PREVIATO L., DICHEK H., BRUNZELL J.D., BREWER H.B., SANTAMARINA-FOJO S. Human lipoprotein lipase: Analysis of the catalytic triad by site-directed mutagenesis of Ser 132, Asp 156 and His 241. *J Biol Chem* 1992;267:4161-4165.
 9. VIDAUD D., EMMERICH J., ALHENC-GELAS M., YVART J., FIESSINGER J.N., AIACH M. Meth 358 to Arg mutation of alpha1-antitrypsin associated with protein C deficiency in a patient with mild bleeding tendency. *J Clin Invest* 1992;89:1537-1545.
 10. EMMERICH J., DELAHAYE F., BRUCKERT E., THOMAS D., RICHARD J.L. Faut-il traiter les femmes hypercholestérolémiques ? . *Arch Mal Coeur* 1992;85(III):73-78.

11. EMMERICH J., THOMAS D., RICHARD J.L., DELAHAYE F., BRUCKERT E. Cholestérolémie souhaitable et efficacité des mesures visant à abaisser la cholestérolémie. Arch Mal Coeur 1992;85(III):59-65.
12. EMMERICH J., BRUCKERT E., DELAHAYE F., THOMAS D., RICHARD J.L. Relation entre HDL-cholestérol et maladies cardiovasculaires. Arch Mal Coeur 1992;85(III):21-28.
13. DELAHAYE F., EMMERICH J., E., THOMAS D., RICHARD J.L. Faut-il se comporter chez les hommes de 20 à 30 ans hypercholestérolémiques comme chez les hommes plus âgés ? Arch Mal Coeur 1992;85(III):67-72.
14. BRUCKERT E., EMMERICH J., DELAHAYE F., RICHARD J.L., THOMAS D. Rôle des triglycérides dans les maladies cardiovasculaires. Arch Mal Coeur 1992;85(III):29-35.
15. THOMAS D., RICHARD J.L., EMMERICH J., BRUCKERT E., DELAHAYE F. La régression de l'athérosclérose est-elle possible? Arch Mal Coeur 1992;85(III):47-57.
16. RICHARD J.L., BRUCKERT E., DELAHAYE F., EMMERICH J., THOMAS D. Taux de cholestérol sanguin et mortalité. Arch Mal Coeur 1992;85(III):11-19.
17. DELAHAYE F., BRUCKERT E., THOMAS D., EMMERICH J., RICHARD J.L. Cholestérolémie et cancer : s'agit-il d'une relation de cause à effet. Arch Mal Coeur 1992;85(III):37-45.
18. BRUCKERT E., DELAHAYE F., RICHARD J.L., EMMERICH J., THOMAS D. Hyperlipidémie chez le sujet âgé de plus de 60 ans. Arch Mal Coeur 1992;85(III):79-82.
19. AIACH M., GANDRILLE S., EMMERICH J., ALHENC-GELAS M., FIESSINGER J.N. Molecular abnormalities responsible for thrombosis. Genetic aspects. N Revue Franç Hématol 1992;34:279-285.
20. EMMERICH J., VERGES B., TAUVERON I., RADER D., SANTAMARINA-FOJO S., AYRAULT-JARRIER M., THIEBLOT P., BREWER H.B., Jr. Familial high density lipoprotein deficiency due to hypercatabolism of normal apolipoprotein A-I. Arteriosclerosis and Thrombosis 1993;13:1299-1306.
21. DEHAINE-BAMBERGER N., AMAR R., TOUBOUL C., EMMERICH J., FIESSINGER J.N. Maladie de Buerger: aspects cliniques et pronostiques. Presse Médicale 1993;22:945-948.
22. LANE D.A., OLDS R.J., BOISCLAIR M., CHOWDHURY V., THEIN S.L., COOPER D.N., BLAJCHMAN M., PERRY D., EMMERICH J., AIACH M. Antithrombin III Mutation Database: first update. For the Thrombin and its inhibitors subcommittee of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thrombosis and Haemostasis 1993;70:361-369.
23. ACAR P., EMMERICH J., ACAR C., CAPRON L., FIESSINGER J.N. Endocardite à Staphylococcus aureus: présentation clinique inhabituelle. Revue de Médecine Interne 1993;14:733-736.
24. EMMERICH J., BEYSSEN B., FIESSINGER JN, GAUX JC. La thrombo-aspiration percutanée: une alternative à l'embolotomie chirurgicale par sonde de Fogarty. Presse Médicale 1993;22:1765-1766.
25. LORTHOLARY O., EMMERICH J., BUU HOI A., GUTMANN L., FIESSINGER J.N., ACAR J.F. Endocardite sur valve native à Lactobacillus casei subspecies casei . Méd Mal Inf 1994;24:110-111.
26. BRUCKERT E., EMMERICH J., THOMAS D., CHARPAK Y., BICHON L., CLERGEOT A. Influence d'une campagne d'information sur les facteurs de risque cardiovasculaire dans une ville française (Eperon, Ville d'Etude): méthodologie et résultats préliminaires. Revue d'Epidémiologie et de Santé Publique. 1994;42:128-137.
27. GAUSSEM P., GANDRILLE S., DUCHEMIN J., EMMERICH J., ALHENC-GELAS M., AILLAUD MF., AIACH M. Influence of six mutations of the protein C gene on the Gla domain conformation and calcium affinity. Thrombosis and Haemostasis 1994;71:748-54..
28. EMMERICH J., ALHENC-GELAS M., FIESSINGER J.N., AIACH M. Une nouvelle cause de thrombophilie familiale: La résistance à l'action de la protéine C activée. Presse Médicale 1994;23:1285-7.
29. EMMERICH J., CHADEUF G., ALHENC-GELAS M., GOUAULT-HEILMANN M., TOULON P., FIESSINGER J.N., AIACH M. Molecular basis of antithrombin type I deficiency: the first large in-frame deletion and two novel mutations in exon VI. Thrombosis and Haemostasis 1994;72:534-9.
30. GANDRILLE S., JUDE B., ALHENC-GELAS M., EMMERICH J., AIACH M. First de novo mutations in the protein C gene of two patients with type I deficiency : A missense mutation and a splice site deletion. Blood 1994;84:2566-70.
31. EMMERICH J., CHADEUF G., COETZEE M.J., ALHENC-GELAS M., FIESSINGER J.N., AIACH M. Phenylalanine 402 to Leu mutation is probably responsible for a stable inactive conformation of

antithrombin. *Thrombosis Research* 1994;76:307-15.

32. EMMERICH J., VIDAUD D., ALHENC-GELAS M., CHADEUF G., GOUAULT-HEILMANN M., AILLAUD M.F., AIACH M. Three novel mutations of antithrombin inducing high-molecular-mass compounds. *Arteriosclerosis and Thrombosis*. 1994;14:1958-65.

33. ALHENC-GELAS M., EMMERICH J., GANDRILLE S., AUBRY M.L., BENAILY N., FIESSINGER J.N., AIACH M. Protein C perfusion in a patient with inherited protein C deficiency caused by two missense mutations: Arg 178 to Gln and Arg -1 to His. *Blood Coagulation and Fibrinolysis* 1994;6:35-41.

34. EMMERICH J., ALHENC-GELAS M., GANDRILLE S., GUICHET C., FIESSINGER J.N., AIACH M. Mechanism of protein C deficiency in a patient with arginine 358 a1-antitrypsin (Pittsburgh mutation). Role in the maintenance of hemostatic balance. *J Lab Clin Med*. 1995;125:531-9.

35. AIACH M., GANDRILLE S., EMMERICH J. A review of mutations causing deficiencies of antithrombin, protein C and protein S. *Thrombosis and Haemostasis* 1995;74:81-89.

36. VEYSSIER-BELOT C., EMMERICH J., SAPOVAL M., BEYSSSEN B., HOFFMAN O., RAYNAUD A., GAUX J.C., FIESSINGER J.N. Percutaneous transluminal angioplasty for emboligenic arterial lesions after radiotherapy of axillary arteries. *J Vascular Surgery* 1995;22:118-9.

37. GANDRILLE S., AIACH M., ABGRALL J.F., ALHENC-GELAS M., EMMERICH J., AILLAEUD M.F., JUHAN-VAGUE I., BOINOT C., DENNINGER M.H., DREYFUS M., DUPUY E., MOLHO-SABATIER P., FISCHER A.M., FORESTIER F., GOUAULT-HEILMANN M., HOUBOUYAN L., HOURDILLE P., JUDE B., MICHAUD-MALLET A., DE MOERLOOSE P., REBER G., POMMEREUIL M., REYNAUD J., ROUSSI J., SAMPOL J., SIÉ P., TOULON P. Identification of mutations in 90 of 121 consecutive French patients with a type I protein C deficiency. *Blood* 1995;86:2598-605.

38. ESCOFFRE-BARBE M., ALHENC-GELAS M., AIACH M., EMMERICH J. Absence of length polymorphism within the 31 tandem repeats of the B domain of factor V. *Thrombosis and Haemostasis* 1996;75:862-63.

39. EMMERICH J. Les serpins, une classe de protéines fonctionnellement importantes : le paradigme de l'alpha-1-antitrypsine. *Revue de Médecine Interne* 1996;17:176-9.

40. EMMERICH J., ALHENC-GELAS M., AIACH M., FIESSINGER J.N. La résistance à l'action de la protéine C activée : rôle dans la thrombose veineuse et artérielle. *Archives des Maladies du Coeur et des Vaisseaux*. 1996;89:741-5.

41. PERRIER E., EMMERICH J., FIESSINGER J.N. Acropathie ulcéro-mutilante chez une femme de 42 ans. *Revue de Médecine Interne* 1996;17(Suppl 2):223-5.

42. BEYSSSEN B., SAPOVAL M., EMMERICH J., JULIA P., GAUX J.C. Ischémie aiguë fémoro-poplitée. Nouvelle approche thérapeutique. Place respective de la thrombo-aspiration et de la thrombolyse in situ. *Chirurgie* 1996;121:127-32.

43. SALEUN S., DE MOERLOOSE P., BUR A., AIACH M., EMMERICH J. A novel nonsense mutation in the antithrombin 3 gene (Cys -4 -> Stop) causing recurrent venous thrombosis. *Blood Coagulation and Fibrinolysis* 1996;7:578-9.

44. BAUTERS A., ZAWADSKI C., BUR A., THERY C., WATEL A., SUBTIL D., AIACH M., EMMERICH J., JUDE B.

Homozygous variant of antithrombin III with lack of affinity heparin : management of severe thrombotic complications associated with foetal death. *Blood Coagulation and Fibrinolysis* 1996;7:705-10.

45. LANE D.A., BAYSTON T., OLDS R.J., FITCHES A.C., COOPER D.N., MILLAR D.S., JOCHMANS K., PERRY D.J., OKAJIMA K., THEIN S.L., EMMERICH J. Antithrombin mutation database: 2nd (1997) update. For the plasma coagulation inhibitors subcommittee of the scientific and standardization committee of the international society on thrombosis and haemostasis. *Thromb Haemost* 1997;77:197-211.

46. RANCE A., EMMERICH J., OGER E., FIESSINGER J.N. Maladie thromboembolique et cancers occultes : Quel bilan réaliser ? propos de 204 patients. *Arch. Mal. Coeur* 1997;90:209-14.

47. EMMERICH J., ALHENC-GELAS M., AILLAUD M.F., JUHAN-VAGUE I., JUDE B., GARCIN J.M., DREYFUS M., DE MOERLOOSE P., LE QUERREC A., PRIOLLET P., BERRUYER M., VALLANTIN X., WOLF M., AIACH M., FIESSINGER J.N. Clinical features in 36 patients homozygous for the Arg 506 - Gln factor V mutation. *Thrombosis Haemostasis* 1997;77:620-3.

48. JACQ F., EMMERICH J., HERON E., LORTHOLARY O., BRUNEVAL P., FIESSINGER J.N. Gangrène distale et cryoglobulinémie liée à l'infection par le virus de l'hépatite C avec présence d'anticorps anticardiolipines. *Revue de Médecine Interne* 1997;18:324-27.

49. JACQ F., HERON E., RANCE A., CESARINI M.L., EMMERICH J., FIESSINGER J.N. Evaluation d'un test de détection rapide des D-dimères pour l'exclusion du diagnostic de thrombose veineuse.

Presse Med 1997 ;26 :1132-4.

50. AIACH M., BORGEL D., GAUSSEM P., EMMERICH J., ALHENC-GELAS M., GANDRILLE S. Protein C and Protein S Deficiencies. *Seminars in Hematology* 1997 ;34 :205-17.

51. HERRMANN S-M., POIRIER O., MARQUEZ-VIDAL P., EVANS A., ARVEILER D., LUC G., EMMERICH J., CAMBIEN F. The Leu 33/Pro polymorphism (PIA1/PIA2) of the glycoprotein IIIa (GP IIIa) receptor is not related to CHD in the ECTIM-study. *Thromb Haemost.* 1997 ;77 :1179-81.

52. GARCIN JM., PLOTTON N., COLLET JP., ALHENC-GELAS M., EMMERICH J., CHANUDET X., LARROQUE P. La résistance à la protéine C activée dans la maladie thromboembolique veineuse. *Sem Hôp Paris* 1997;73 :793-99.

53. Participation à l'étude Thésée. SIMONNEAU G., SORS H., CHARBONNIER B., for the THESEE Study Group. A comparison of low molecular weight heparin with unfractionated heparin for acute pulmonary embolism. *N Engl J Med* 1997 ;337 :663-9.

54. RANCE A., EMMERICH J., GUEDJ C., FIESSINGER JN. Occult cancer in patients with bilateral deep vein thrombosis. *Lancet (Research Letter)* 1997;350 :1448-9.

55. EMMERICH J. Acrosyndrome au cours du SIDA. La toxicité de la bléomycine redécouverte. *Presse Méd* 1997 ;26 :1580-1.

56. QUERE I., EMMERICH J. Les nouvelles causes de thrombophilie constitutionnelle. *Rev Méd Interne* 1997 ;18(Suppl 6) :626s-35s.

57. BENHAMOU A.C., DADON M., EMMERICH J., FONTAINE P., GOT I., GUILLAUSSÉAU P.J., PERNES J.M., PRIOLLET P. Artériopathie des membres inférieurs chez le diabétique. *Diabetes Metab* 1997 ;23 :541-8.

58. Participation à l'étude Prépic. DECOUSUS H., LEIZOROVICZ A., PARENT F., et al. for the Prévention du Risque d'Embolie Pulmonaire par Interruption Cave study group. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. *N Engl J Med* 1998 ;338 :409-15.

59. HERON E., FORNES P., RANCE A., EMMERICH J., BAYLE O., FIESSINGER JN. Brain involvement in scleroderma. Two autopsy cases. *Stroke* 1998 ;29 :719-21.

60. LOZINGUEZ O., EMMERICH J., FORNES P., FIESSINGER JN. Léiomyosarcome de la veine cave inférieure. *Presse Med* 1998 ;27 :855-7.

61. PIQUEMAL R., EMMERICH J., GUILMOT JL., FIESSINGER JN. Successful treatment of ergotism with Iloprost. A case report. *Angiology* 1998 ;49 :493-7.

62. EMMERICH J. Anomalies lipidiques : facteur favorisant ou agent étiologique de l'athérosclérose. *Arch Mal Coeur* 1998 ;91(suppl IV) :13-19.

63. EMMERICH J., FIESSINGER JN. Epidémiologie et facteurs étiologiques des artérites à cellules géantes (maladie de Horton et maladie de Takayasu). *Ann Med Interne* 1998 ;149 :425-32.

64. ALHENC-GELAS M., NICAUD V., GANDRILLE S., VAN DREDEN P., AMIRAL J., AUBRY M-L., FIESSINGER J-N., EMMERICH J., AIACH M. The factor V gene A4070G mutation and the risk of venous thrombosis. *Thromb Haemost* 1999 ;81 :193-7.

65. LE FLEM L., PICARD V., EMMERICH J., GANDRILLE S., FIESSINGER J.N., AIACH M., ALHENC-GELAS M. Mutations in promoter region of thrombomodulin and venous thromboembolic disease. *Arterioscl Thromb Vasc Biol* 1999 ;19 :1098-104.

66. ALHENC-GELAS M., ARNAUD E., NICAUD V., AUBRY M-L., FIESSINGER J-N., EMMERICH J. Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes. *Thromb Haemost* 1999 ;81 :506-10.

67. BRUCKERT E., THOMAS D., EMMERICH J., BLIN P., BICHON L., AMELINEAU E. Influence d'une campagne d'information sur les facteurs de risque cardio-vasculaires. Eperon ville d'étude, résultats à 5 ans. *Presse Med* 1999 ;28 :517-22.

68. VELUT J.G., HERON E., EMMERICH J., BEYSSEN B., SAPOVAL M., LOZINGUEZ O., VANDEKERCKHOVE C., GAUX J.C., FIESSINGER J.N. Résultats immédiats et à 2 ans de l'angioplastie transluminale percutanée dans la claudication intermittente du sujet âgé de plus de 70 ans. *Revue de Médecine Interne* 1999;20:323-28.

69. AIACH M., NICAUD V., ALHENC-GELAS M., GANDRILLE S., ARNAUD E., AMIRAL J., GUIZE L., FIESSINGER JN., EMMERICH J. Complex association of protein C gene promoter polymorphism with circulating protein C levels and the thrombotic risk. *Arterioscl Thromb Vasc Biol* 1999 ;19 :1573-6.

70. LOZINGUEZ O., ARNAUD E., VELUT J.G., TIEV K.P., FIESSINGER J.N., EMMERICH J. Cytomegalovirus et pathologies artérielles : aspects actuels. *Arch Mal Coeur* 1999 ;92 :1205-12.

71. HERON E., LOZINGUEZ O., EMMERICH J., LAURIAN C., FIESSINGER J.N. Long-term

- sequelae of spontaneous axillary-subclavian vein thrombosis. *Ann Intern Med.* 1999 ;131 :510-3.
72. LE CAM-DUCHEZ V., GANDRILLE S., TREGOUET D., ALHENC-GELAS M., EMMERICH J., FIESSINGER J.N., BORG J.Y., AIACH M. Influence of three potential genetic risk factors for thrombosis in 43 families carrying the factor V Arg 506 to Gln mutation. *Br J Haematol* 1999 ;106 :889-97.
73. EMMERICH J. Embolie pulmonaire : la technique, les indications et l'impact diagnostique des explorations des membres inférieurs. *Rev Mal Resp* 1999 ;16 :919-26.
74. HERON E., LOZINGUEZ O., ALHENC-GELAS M., EMMERICH J., FIESSINGER J.N. Hypercoagulable states in primary upper-extremity deep vein thrombosis. *Arch Intern Med*, 2000 ; 160 :382-6.
75. ARNAUD E., NICAUD V., POIRIER O., RENDU F., ALHENC-GELAS M., FIESSINGER J.N., EMMERICH J., AIACH M. Protective effect of a thrombin receptor (PAR-1) gene polymorphism towards venous thromboembolism. *Arterioscl Thromb Vasc Biol* 2000 ; 20:585-92.
76. ARNAUD E., BARBALAT V., NICAUD V., CAMBIEN F., EVANS A., MORRISON C., ARVEILER D., LUC G., RUIDAVETS J.B., EMMERICH J., FIESSINGER J.N., AIACH M. Polymorphisms in the 5' regulatory region of the tissue factor gene and the risk of myocardial infarction and venous thromboembolism : the ECTIM and PATHROS studies. *Arterioscl Thromb Vasc Biol* 2000 ; 20:892-898.
77. LOZINGUEZ O., ARNAUD E., BELEC L., NICAUD V., ALHENC-GELAS M., FIESSINGER J.N., AIACH M., EMMERICH J. Demonstration of an association between Chlamydia pneumoniae infection and venous thromboembolic disease. *Thromb Haemost* 2000;83:887-91.
78. KOSTER T., ROSENDAAL F.R., LIEUW-A-LEN D.D., KROES A.C.M., EMMERICH J.D., VAN DISSEL J.T. Chlamydia pneumoniae IgG seropositivity and risk of deep-vein thrombosis. *Lancet (Research Letter)* 2000;355:1694-5.
79. PAUL J.F., FIESSINGER J.N., HERNIGOU A., SAPOVAL M., EMMERICH J., GAUX J.C. Embolie pulmonaire : la scintigraphie pulmonaire est-elle utile en seconde intention ? *J Radiol* 2000;81:882-4.
80. PICARD V., BURA A., EMMERICH J., ALHENC-GELAS M., BIRON C., HOUBOUYAN-REVEILLARD LL, MOLHO P, LABATIDE-ALANORE A., SIE P., TOULON P., VERDY E., AIACH M. Molecular bases of antithrombin deficiency in French families : identification of seven novel mutations in the antithrombin gene. *Br J Haematology* 2000;110:731-4.
81. LE FLEM L., MENNEN L., AUBRY M-L., AIACH M., SCARABON P-Y., EMMERICH J., ALHENC-GELAS M. Thrombomodulin promoter mutations, venous thrombosis, and varicose veins. *Arterioscler Thromb Vasc Biol* 2001;21:445-51.
82. MEYER G., EMMERICH J., HELLEY D., ARNAUD E., NICAUD V., ALHENC-GELAS M., AIACH M., FISCHER AM., SORS H., FIESSINGER JN. Factors V Leiden and II 20210A allele in patients with symptomatic pulmonary embolism and deep vein thrombosis. *Am J Med* 2001;110:12-15.
83. EMMERICH J. Le syndrome de la classe économique : mythe ou réalité et quelle prévention. *Revue de Médecine Interne* 2001;22:425-7
84. EMMERICH J., ROSENDAAL F.R., CATTANEO M., MARGAGLIONE M., DE STEFANO V., CUMMING T., ARRUDA V., HILLARP A., RENY J.L., for the study group for pooled-analysis in venous thromboembolism. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism. Pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. *Thromb Haemost* 2001;86:809-16.
85. PAUL J.F., FIESSINGER J.N., SAPOVAL M., HERNIGOU A., MOUSSEAUX E., EMMERICH J., PIETTE J.C. Follow-up electron beam CT for the management of early phase Takayasu arteritis. *J Comput Assist Tomogr* 2001;25:924-31.
86. EMMERICH J. Looking for deep vein thrombosis in pulmonary embolism. *Semin Vasc Med* 2001;1:181-7.
87. POSZEPZYNSKA-GUIGNE E., VIGUIER M., CHOSIDOW O., ORCEL B., EMMERICH J., DUBERTRET L. Clinical, epidemiological and evolutive features of acrosyndrom associated with malignancy. *J Am Acad Dermatol* 2002;47:47-52.
88. EMMERICH J, AIACH M. Facteurs génétiques de risque de thrombose. *Annales de Cardiologie et d'Angéiologie* 2002;51:129-34.
89. AMEZIANE N, SEGUIN C, BORGEL D, FUMERON F, MOATTI D, ALHENC-GELAS M, GRANDCHAMP B, AIACH M, EMMERICH J, DE PROST D. The -33T/C polymorphism in intron 7 of the TFPI gene influences the risk of venous thromboembolism, independently of the factor V Leiden and prothrombin mutations. *Thromb Haemost* 2002 88:195-9.
90. HERON E, HERNIGOU A, FORNES P, CHATELLIER G, EMMERICH J, FIESSINGER JN.

- Atteinte du système nerveux central dans la sclérodémie. *Ann Med Interne* 2002 ;153 :179-82.
91. EMMERICH J. Thrombose et antithrombotiques dans la pathologie vasculaire des membres inférieurs. *Arch mal Cœur* 2002 ;95(VII) :59-62.
92. BORGEL D, RENY JL, FISCHÉLIS D, GANDRILLE S, EMMERICH J, FIESSINGER JN, AIACH M. Cleaved Protein S (PS), Total PS, Free PS, and Activated Protein C Cofactor Activity as Risk Factors for Venous Thromboembolism. *Clin Chem* 2003;49:575-80.
93. RENY JL, PAUL JF, LEFEBVRE C, CHAMPION K, EMMERICH J, BLETRY O, PIETTE JC, FIESSINGER JN. Association of Takayasu's arteritis and Crohn's disease. *Ann Med Interne* 2003;154:85-90.
94. EMMERICH J. Infection and venous thrombosis. *Pathophysiol Haemost Thromb* 2002;32: 346-8.
95. RICCI MA, EMMERICH J, CALLAS PW, ROSENDAAL FR, STANLEY AC, NAUD S, VOSSEN C, BOVILL EG. Evaluating chronic venous disease with a new venous severity scoring system. *J Vasc Surg* 2003;38:909-15.
96. FONTANA P, GAUSSEM P, AIACH M, FIESSINGER JN, EMMERICH J, RENY JL. P2Y12 H2 haplotype is associated with peripheral arterial disease. A case-control study. *Circulation* 2003;108:2971-3.
97. PERDU J, BAQUE J, EMMERICH J, FIESSINGER JN, SAPOVAL M. Subintimal angioplasty. Technique, results and role in the treatment of peripheral arterial occlusive disease. *J Mal Vasc*. 2003;28:245-50.
98. SAPOSNIK B, RENY JL, GAUSSEM P, EMMERICH J, AIACH M, GANDRILLE S. A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosis. *Blood* 2004;103:1311-8.
99. RENY JL, LAURENDEAU I, FOPNTANA P, BIECHE I, DUPONT A, REMONES V, EMMERICH J, VIDAUD M, AIACH M, GAUSSEM P. The TF -603A/G gene promoter polymorphism and circulating monocyte tissue factor gene expression in healthy volunteers. *Thromb Haemost* 2004;91:248-54.
100. BURA A, CAILLEUX N, BIENVENU B, LEGER P, BISSERY A, BOCCALON H, FIESSINGER JN, LEVESQUE H, EMMERICH J. Incidence and prognosis of cancer associated with bilateral venous thrombosis: a prospective study of 103 patients. *J Thromb Haemost*. 2004;2:441-4.
101. PERDU J, CHAMPION K, EMMERICH J, FIESSINGER JN. Microangiopathie du pseudoxanthome élastique. Aspects capillaroscopiques. *Press Med* 2004;33:515-8.
102. RENY JL, ALHENC-GELAS M, FONTANA P, BISSERY A, JULIA PL, FIESSINGER JN, AIACH M, EMMERICH J. The factor II G20210A gene polymorphism but not factor V Arg506Gln, is associated with peripheral arterial disease: results of a case-control study. *J Thromb Haemost* 2004;2:1334-40.
103. AUJESKY DA, CORNUZ J, BOSSON JL, BOUNAMEAUX H, EMMERICH J, HULL RD, MACKAY E, PERRIER E, QUAN H, TSUYUKI RT, GHALI W. Uptake of new treatment strategies for deep vein thrombosis : an international audit. *International Journal for Quality in Health Care* 2004 ; 16 :193-200.
104. EMMERICH J. Traitement médical, thérapie génique et cellulaire de l'AOMI. *Presse Médicale* 2004;33:1099-101.
105. EMMERICH J, LE HEUZEY JY, BATH PMW, CONNOLLY SJ. Indication for antithrombotic therapy for atrial fibrillation: reconciling the guidelines with clinical practice. *Eur Heart J* 2005;7 (Suppl C):28-33.
106. EMMERICH J, VOSSEN CY, CALLAS PW, DEMERS C, NAUD S, LONG GL, COUTURE P, ROSENDAAL FR, BOVILL EG. Chronic venous abnormalities in symptomatic and asymptomatic protein C deficiency. *J Thromb Haemos*. 2005 ;3:1428-31.
107. BOCCALON H, BONEU B, EMMERICH J, THALAMAS C, RUIDAVETS JB. Long-haul flights do not activate haemostasis in young healthy men. *J Thromb Haemost* 2005;3:1539-40.
108. ROSENCHER N, VIELPEAU C, EMMERICH J, FAGNANI F, SAMAMA CM. Venous Thromboembolism and Mortality after Hip Fracture surgery: The ESCORTE Study. *J Thromb Haemost* 2005;3:2006-14.
109. TOLEDANO C, HENEGAR C, ILIE D, LAUNAY D, TIEV K, MARIE I, MARJANOVIC Z, EMMERICH J, CABANE J, MENASCHE S, FARGE D. Etude de la fonction cardiopulmonaire avant et après traitement par cyclophosphamide dans la sclérodémie systémique sévère : comparaison de deux modes d'administration (Intensification thérapeutique dsuivie d'autogreffe de cellules souches hématopoïétiques périphériques ou bolus mensuels intraveineux). *Revue Med Interne* 2005 ;26:444-52.

110. FAVIER J, GERMAIN S, EMMERICH J, CORVOL P, GASC JM. Critical overexpression of thrombospondin-1 in chronic leg ischemia. *J Pathol* 2005;207:358-66.
111. STRACZEK C, OGER E, YON DE JONAGE-CANONICO MB, PLU-BUREAU G, CONARD J, MEYER G, ALHENC-GELAS M, LEVESQUE H, TRILLOT N, BARRELLIER MT, WAHL D, EMMERICH J, SCARABIN PY. Prothrombotic Mutations, Hormone Therapy, and Venous Thromboembolism Among Postmenopausal Women. Impact of the Route of Estrogen Administration. *Circulation*. 2005;112:3495-500.
112. EMMERICH J. Current state and perspective on medical treatment of critical leg ischemia: gene and cell therapy. *Int J Low Extrem Wounds* 2005;4:234-4.
113. SIMON T, BEAU YON DE JONAGE-CANONICO M, OGER E, WAHL D, CONARD J, MEYER G, EMMERICH J, BARRELLIER MT, GUIRAUD A, SCARABIN PY. EStrogen and ThromboEmbolism Risk (ESTHER) Study Group. Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism. *J Thromb Haemost*. 2006;4:71-6.
114. PERDU J, GIMENEZ-ROQUEPLO AP, BOUTOUYRIE P, BEAUJOUR S, LALOUEX B, NAU V, FIQUET-KEMPF B, EMMERICH J, TICHET J, PLOUIN PF, LAURENT S, JEUNEMAITRE X. α 1-antitrypsin gene polymorphisms are not associated with renal arterial fibromuscular dysplasia. *J Hypertension* 2006;24 :705-10.
115. ZIVELIN A, MOR-COHEN R, KOVALSKY V, KORNBROT N, CONARD J, PEYVANDI F, KYRLE PA, BERTINA R, PEYVANDI F, EMMERICH J, SELIGSOHN U. Prothrombin G20210A is an ancestral prothrombotic mutation that occurred in caucasians approximately 24,000 years ago. *Blood* 2006; 107:4666-8.
116. CANONICO M, OGER E, CONARD J, MEYER G, LEVESQUE H, TRILLOT N, BARRELLIER MT, WAHL D, EMMERICH J, SCARABIN PY; EStrogen and THromboEmbolism Risk (ESTHER) study group. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. *J Thromb Haemost*. 2006;4:1259-65.
117. ROSENCHER N, VIELPEAU C, EMMERICH J, SAMAMA CM. More on: venous thromboembolism and mortality after hip fracture: the ESCORTE study. *J Thromb Haemost*. 2006 ;4:1645-7.
118. EMMERICH J, MEYER G, DECOUSUS H, AGNELLI G. Role of fibrinolysis and interventional therapy for acute venous thromboembolism. *Thromb Haemost* 2006;96:251-7.
119. BECATTINI C, AGNELLI G, EMMERICH J, BURAA, WEITZ JI. Initial treatment of venous thromboembolism. *Thromb Haemost*. 2006;96:242-50.
120. SMADJA DM, BIECHE I, EMMERICH J, AIACH M, GAUSSEM P. PAR-1 activation has different effects on the angiogenic activity of endothelial progenitor cells derived from human adult and cord blood. *J Thromb Haemost*. 2006;4:2729-31.
121. KAC G, GUENERET M, RODI A, ABERGEL E, GRATALOUP C, DENARIE N, PEYRARD S, CHATELLIER G, EMMERICH J, MEYER G, PODGLAJEN I. Evaluation of a new disinfection procedure for ultrasound probes using ultraviolet light. *J Hosp Infect* 2007;65:163-8
122. STEICHEN O, PELLERIN O, FRANK M, EMMERICH J, SAPOVAL M, FIESSINGER JN, BURARIVIERE A. Traitement par voie endovasculaire d'un faux anévrisme tuberculeux de l'isthme aortique. *Rev Med Interne* 2007;28:196-8.
123. CANONICO M, OGER E, PLU-BUREAU G, CONARD J, MEYER G, LÉVESQUE H, TRILLOT N, BARRELLIER MT, WAHL D, EMMERICH J, SCARABIN PY for the Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study. *Circulation* 2007;115:840 – 845.
124. SMADJA DM, CORNET A, EMMERICH J, AIACH M, GAUSSEM P. Endothelial progenitor cells: Characterization, in vitro expansion, and prospects for autologous cell therapy. *Cell Biol Toxicol*. 2007;23:223-39.
125. WILHELM C., BAL L., SMIRNOV P., GALY-FAUROUX I., CLEMENT O., GAZEAU F., EMMERICH J. Magnetic control of vascular network formation with magnetically labeled endothelial progenitor cells. *Biomaterials*. 2007;28:3797-806
126. ZEE RY, MICHAUD SE, DIEHL KA, CHASMAN DI, EMMERICH J, GAUSSEM P, AIACH M, RIDKER PM. Purinergic receptor P2Y₂, G-protein coupled, 12 gene variants and risk of incident ischemic stroke, myocardial infarction, and venous thromboembolism. *Atherosclerosis* 2008;197:694-9.
127. CLAUSER S, PEYRARD S, GAUSSEM P, CRESPIEN M, EMMERICH J, AIACH M, BORGEL D.

- Development of a novel immunoassay for the assessment of plasma Gas6 concentrations and their variation with hormonal status. *Clin Chem.* 2007;53:1808-13.
128. FLAUJAC C, POUARD P, BOUTOUYRIE P, EMMERICH J, BACHELOT-LOZA C, LASNE D. Platelet dysfunction after normothermic cardiopulmonary bypass in children: effect of high-dose aprotinin. *Thromb Haemost.* 2007;98:385-91.
129. EMMERICH J. Atherothrombosis risk factors: too many and too little. *J Thromb Haemost.* 2007;5:1793-4.
130. SERVE E, RENY JL, AKHAVAN S, EMMERICH J, FISCHER AM, TAPON-BRETAUDIÈRE J. A two adenine insertion polymorphism in the 3' untranslated region of factor VII gene is associated with peripheral arterial disease but not with venous thrombosis. Results of case-control studies. *Thromb Haemost.* 2007;98:733-7.
131. DUONG VAN HUYEN JP, SMADJA D, BRUNEVAL P, GAUSSEM P, DAL-CORTIVO L, JULIA P, FIESINGER JN, CAVAZZANA-CALVO M, AIACH M, EMMERICH J. Bone marrow-derived mononuclear cell therapy induces distal angiogenesis after local injection in critical leg ischemia. *Modern Pathology* 2008;21:837-46.
132. EMMERICH J, RIDKER P. Can fishing for new genes catch patients at risk of coronary artery disease ? *Clin Chemistry* 2008;54: 453-5.
133. NIKOL S, BAUMGARTNER I, VAN BELLE E, DIEHM C, VISONA A, CAPOGROSSI M, FERREIRA-MALDENT N, GALLINO A, WYATT MG, WIJESINGHE LD, FUSARI M, STEPHAN D, EMMERICH J, POMPILIO G, VERMASSEN F, PHAM E, GREK V, COLEMAN M, MEYER F. Therapeutic Angiogenesis With Intramuscular NV1FGF Improves Amputation-Free Survival in Patients With Critical Limb Ischemia. *Molecular Therapy* 2008;16:972-8.
134. SMADJA DM, LORIOT MA, HINDORFF LA, MELLOTTÉE L, GAUSSEM P, EMMERICH J. No clear link between VKORC1 genetic polymorphism and the risk of venous thrombosis or peripheral arterial disease. *Thromb Haemost.* 2008;99:970-972.
135. SMADJA DM, BIECHE I, SUSEN S, MAUGE L, LAURENDEAU I, D'AUDIGIER C, GRELAC F, EMMERICH J, AIACH M, GAUSSEM P. Interleukin 8 is differently expressed and modulated by PAR-1 activation in early and late endothelial progenitor cells. *J Cell Mol Med.* 2008 Jul 23.
136. SMADJA DM, BIÈCHE I, SILVESTRE JS, GERMAIN S, CORNET A, LAURENDEAU I, DUONG-VAN-HUYEN JP, EMMERICH J, VIDAUD M, AIACH M, GAUSSEM P. Bone Morphogenetic Proteins 2 and 4 Are Selectively Expressed by Late Outgrowth Endothelial Progenitor Cells and Promote Neoangiogenesis. *Arterioscler Thromb Vasc Biol.* 2008;28:2137-43.
137. ZHU T, MARTINEZ I, EMMERICH J. Venous thromboembolism: risk factors for recurrence. *Arterioscler Thromb Vasc Biol.* 2009;29:298-310.
138. TRÉGOUËT DA, HEATH S, SAUT N, BIRON-ANDREANI C, SCHVED JF, PERNOD G, GALAN P, DROUET L, ZELENKA D, JUHAN-VAGUE I, ALESSI MC, TIRET L, LATHROP M, EMMERICH J, MORANGE PE. Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. *Blood.* 2009;113:5298-303.
139. EMMERICH J. Alpha1-antitrypsin and the maintenance of hemostatic balance. *Haematologica.* 2009;94:762-3.
140. PICARD V, CHEN JM, TARDY B, AILLAUD MF, BOITEUX-VERGNES C, DREYFUS M, EMMERICH J, LAVENU-BOMBLÉD C, NOWAK-GÖTTL U, TRILLOT N, AIACH M, ALHENC-GELAS M. Detection and characterisation of large SERPINC1 deletions in type I inherited antithrombin deficiency. *Hum Genet* 2010;127:45-53.
141. ZHU T, CARCAILLON L, MARTINEZ I, CAMBOU I, KYNDT I, GUILLOT K, VERGNES MC, SCARABIN PY, EMMERICH J. Association of influenza vaccination with reduced risk of venous thromboembolism. *Thrombosis and Haemostasis* 2009;102:1259-64.
142. SMADJA DM, GAUSSEM P, RONCAL C, FISCHER AM, EMMERICH J, DARNIGE L. Arterial and venous thrombosis are associated with different angiogenic cytokine patterns in patients with the antiphospholipid syndrome. *Lupus* 2010;19:837-43
143. DARNIGE L, HELLEY D, FISCHER AM, EMMERICH J, SMADJA DM, FIESINGER JN. Platelet microparticle levels: A biomarker of thromboangiitis obliterans (Buerger's disease) exacerbation. *J Cell Mol Med.* 2009 Oct 10. [Epub ahead of print]
144. BUIL A, TRÉGOUËT DA, SOUTO JC, SAUT N, GERMAIN M, ROTIVAL M, TIRET L, CAMBIEN F, LATHROP M, ZELLER T, ALESSI MC, RODRIGUEZ DE CORDOBA S, MÜNDEL T, WILD P, FONTCUBERTA J, GAGNON F, EMMERICH J, ALMASY L, BLANKENBERG S, SORIA JM, MORANGE PE. C4BPB/C4BPA is a new susceptibility locus for venous thrombosis with unknown protein S independent mechanism: results from genome-wide association and gene expression

analyses followed by case-control studies. *Blood* 2010;115:4644-50.

145. MORANGE PE, BEZEMER I, SAUT N, BARE L, BURGOS G, BROCHETON J, DURAND H, BIRON-ANDREANI C, SCHVED JF, PERNOD G, GALAN P, DROUET L, ZELENKA D, GERMAIN M, NICAUD V, HEATH S, NINIO E, DELLUC A, MÜNDEL T, ZELLER T, BRAND-HERRMANN SM, ALESSI MC, TIRET L, LATHROP M, CAMBIEN F, BLANKENBERG S, EMMERICH J, TRÉGOUËT DA, ROSENDAAL FR. A Follow-Up Study of a Genome-wide Association Scan Identifies a Susceptibility Locus for Venous Thrombosis on Chromosome 6p24.1. *Am J Hum Genet* 2010;86:592-5.
146. MORENO JA, DEJOUVENCEL T, LABREUCHE J, SMADJA DM, DUSSIOT M, MARTIN-VENTURA JL, EGIDO J, GAUSSEM P, EMMERICH J, MICHEL JB, BLANCO-COLIO LM, MEILHAC O. Peripheral Artery Disease Is Associated With a High CD163/TWEAK Plasma Ratio. *Arterioscler Thromb Vasc Biol* 2010;30:1253-62.
147. HINDY-FRANÇOIS C, BACHELOT-LOZA C, LE BONNIEC B, GRELAC F, DIZIER B, GODIER A, EMMERICH J, GAUSSEM P, SAMAMA CM. Recombinant activated factor VII does not reduce bleeding in rabbits treated with aspirin and clopidogrel. *Thromb Haemost.* 2010;104(4):823-30.
148. SNOEP JD, GAUSSEM P, EIKENBOOM JC, EMMERICH J, ZWAGINGA JJ, HOLMES CE, VOS HL, DE GROOT PG, HERRINGTON DM, BRAY PF, ROSENDAAL FR, VAN DER BOM JG. The minor allele of GP6 T13254C is associated with decreased platelet activation and a reduced risk of recurrent cardiovascular events and mortality: results from the SMILE-platelets project. *J Thromb Haemost.* 2010;8:2377-84.
149. COUADE M, PERNOT M, PRADA C, MESSAS E, EMMERICH J, BRUNEVAL P, CRITON A, FINK M, TANTER M. Quantitative Assessment of Arterial Wall Biomechanical Properties Using Shear Wave Imaging. *Ultrasound Med Biol.* 2011;36:1662-75.
150. ONG KT, PERDU J, DE BACKER J, BOZEC E, COLLIGNON P, EMMERICH J, FAURET AL, FIESSINGER JN, GERMAIN DP, GEORGESCO G, HULOT JS, DE PAEPE A, PLAUCHU H, JEUNEMAITRE X, LAURENT S, BOUTOUYRIE P. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. *Lancet* 2010 ;376 :1476-84.
160. GODIER A, DURAND M, SMADJA D, JEANDEL T, EMMERICH J, SAMAMA CM. Maize- or potato-derived hydroxyethyl starches: is there any thromboelastometric difference ? *Acta Anaesthesiol Scand.* 2010;54:1241-7.
161. ALHENC GELAS M, CANONICO M, MORANGE PE, EMMERICH J for the GEHT genetic thrombophilia group. Protein s inherited qualitative deficiency: novel mutations and phenotypic influence. *J Thromb Haemost.* 2010;8:2718-26.
162. GODIER A, DURAND M, EMMERICH J, DIZIER B, LECOMPTE T, SAMAMA CM. Efficacy of prothrombin complex concentrate to reverse the anticoagulant effect of the pentasaccharide fondaparinux in a rabbit model. *Thromb Haemost.* 2011;105:161-8.
163. ANTONI G, MORANGE PE, LUO Y, SAUT N, BURGOS G, HEATH S, GERMAIN M, BIRON-ANDREANI C, SCHVED JF, PERNOD G, GALAN P, ZELENKA D, ALESSI MC, DROUET L, VISVIKIS-SIEST S, WELLS PS, LATHROP M, EMMERICH J, TREGOUET DA, GAGNON F. A multi-stage multi-design strategy provides strong evidence that the BAI3 locus is associated with early-onset venous thromboembolism. *J Thromb Haemost* 2010;8:2671-9.
164. MORANGE PE, SAUT N, ANTONI G, EMMERICH J, Trégouët DA. Impact on venous thrombosis risk of newly discovered gene variants associated with FVIII and VWF plasma levels. *J Thromb Haemost* 2011;9:229-31.
165. SABATIER B, TRINQUART L, EMMERICH J. Dual antiplatelet therapy in the secondary prevention of atherothrombosis: need for new therapeutic approaches. *Arch Cardiovasc Dis.* 2010 ; 103:497-501
166. ABOYANS V, KOWNATOR S, LAFITTE M, BROCHET E, EMMERICH J, TRIBOUILLOY C, LAFITTE S, FERRINI M; Working Group for Vascular Diseases/Thrombosis, French Society of Cardiology; Council of Echocardiography, French Society of Cardiology. Screening abdominal aorta aneurysm during echocardiography: literature review and proposal for a French nationwide study. *Arch Cardiovasc Dis.* 2010 ;103:552-8.
167. SMADJA DM, D'AUDIGIER C, BIÈCHE I, EVRARD S, MAUGE L, DIAS JV, LABREUCHE J, LAURENDEAU I, MARSAC B, DIZIER B, WAGNER-BALLON O, BOISSON-VIDAL C, MORANDI V, DUONG-VAN-HUYEN JP, BRUNEVAL P, DIGNAT-GEORGE F, EMMERICH J, GAUSSEM P. Thrombospondin-1 Is a Plasmatic Marker of Peripheral Arterial Disease That Modulates Endothelial Progenitor Cell Angiogenic Properties. *Arterioscler Thromb Vasc Biol.* 2011;31:551-9.
168. MORANGE PE, OUDOT-MELLAKH T, COHEN W, GERMAIN M, SAUT N, ANTONI G, ALESSI MC, BERTRAND M, DUPUY AM, LETENNEUR L, LATHROP M, LOPEZ LM, LAMBERT JC,

- EMMERICH J, AMOUYEL P, TRÉGOUËT DA. KNG1 Ile58Thr and susceptibility to venous thrombosis. *Blood* 2011;117:3692-4.
169. GERMAIN M, SAUT N, GRELICHE N, DINA C, LAMBERT JC, PERRET C, COHEN W, OUDOT-MELLAKH T, ANTONI G, ALESSI MC, ZELENKA D, CAMBIEN F, TIRET L, BERTRAND M, DUPUY AM, LETENNEUR L, LATHROP M, EMMERICH J, AMOUYEL P, TRÉGOUËT DA, MORANGE PE. Genetics of venous thrombosis : insights from a new genome wide association study. *PLoS One* 2011;6:e25581.
170. SMADJA DM, D'AUDIGIER C, GUERIN CL, MAUGE L, DIZIER B, SILVESTRE JS, CORTIVO LD, GAUSSEM P, EMMERICH J. Angiogenic potential of BM MSCs derived from patients with critical leg ischemia. *Bone Marrow Transplant*. 2011 Oct 10. doi: 10.1038/bmt.2011.196. [Epub ahead of print]
171. SMADJA DM, DUONG-VAN-HUYEN JP, DAL CORTIVO L, BLANCHARD A, BRUNEVAL P, EMMERICH J, GAUSSEM P. Early endothelial progenitor cells in bone marrow are a biomarker of cell therapy success in patients with critical limb ischemia. *Cytotherapy*. 2012;14:232-9
172. GODIER A, MICLOT A, LE BONNIEC B, DURAND M, FISCHER AM, EMMERICH J, MARCHAND-LEROUX C, LECOMPTE T, SAMAMA CM. Evaluation of Prothrombin Complex Concentrate and Recombinant Activated Factor VII to Reverse Rivaroxaban in a Rabbit Model. *Anesthesiology*. 2012;116:94-102
173. SARLON G, ZEMANI F, DAVID L, DUONG VAN HUYEN JP, DIZIER B, GRELAC F, COLLIEC-JOUAULT S, GALY-FAUROUX I, BRUNEVAL P, FISCHER AM, EMMERICH J, BOISSON-VIDAL C. Therapeutic Effect of Fucoidan-Stimulated Endothelial Colony-Forming Cells in Peripheral Ischemia. *J Thromb Haemost*. 2012;10:38-48
174. SAADOUN D, LAMBERT M, MIRAULT T, SCHOINDRE Y, KOSKAS F, CLUZEL P, MIGNOT C, RESCHE-RIGON M, CHICHE L, HATRON PY, EMMERICH J, CACOUB P. Surgery versus Endovascular Repair in Takayasu Arteritis: a Multicenter Study of 166 Procedures. *Circulation*, 2012;125:813-9.
175. COMARMOND C, PLAISIER E, DAHAN K, MIRAULT T, EMMERICH J, AMOURA Z, CACOUB P, SAADOUN D. Anti TNF- α in refractory Takayasu's arteritis: Cases series and review of the literature. *Autoimmun Rev*. 2011 Dec 4.
176. OLIÉ V, ZHU T, MARTINEZ I, SCARABIN PY, EMMERICH J. Sex-specific risk factors for recurrent venous thromboembolism. *Thromb Res*. 2011 Nov 17. [Epub ahead of print]
177. LE SACHÉ F, LE BONNIEC B, GAUSSEM P, DIZIER B, TAGZIRT M, GODIER A, EMMERICH J, SAMAMA CM. Recombinant activated factor VII and prothrombin complex concentrates have different effects on bleeding and arterial thrombosis in the haemodiluted rabbit. *Br J Anaesth*. 2012;108:586-93.
178. FERRÉ FC, FRANK M, GOGLY B, GOLMARD L, NAVEAU A, CHÉRIFI H, EMMERICH J, GAULTIER F, BERDAL A, JEUNEMAITRE X, FOURNIER BP. Oral phenotype and scoring of vascular Ehlers-Danlos syndrome: a case-control study. *BMJ Open*. 2012 Apr 5;2(2): e000705. Print 2012.
179. TREGOUET DA, SABATER-LLEAL M, BRUZELIUS M, EMMERICH J, AMOUYEL P, DARTIGUES JF, KIELER H, MORANGE PE. Lack of association of non synonymous FUT2 and ALPL polymorphisms with venous thrombosis. *J Thromb Haemost*. 2012 Jun 5. doi: 10.1111/j.1538-7836.2012.04807. [Epub ahead of print]
180. GERMAIN M, SAUT N, OUDOT-MELLAKH T, LETENNEUR L, DUPUY AM, BERTRAND M, ALESSI MC, LAMBERT JC, ZELENKA D, EMMERICH J, TIRET L, CAMBIEN F, LATHROP M, AMOUYEL P, MORANGE PE, TRÉGOUËT DA. Caution in Interpreting Results from Imputation Analysis When Linkage Disequilibrium Extends over a Large Distance: A Case Study on Venous Thrombosis. *PLoS One*. 2012;7(6):e38538. Epub 2012 Jun 4.
181. HELGADOTTIR A, GRETARSDOTTIR S, THORLEIFSSON G, HOLM H, PATEL RS, GUDNASON T, JONES GT, VAN RIJ AM, EAPEN DJ, BAAS AF, TREGOUET DA, MORANGE PE, EMMERICH J, LINDBLAD B, GOTTSÄTER A, KIEMENY LA, LINDHOLT JS, SAKALIHASAN N, FERRELL RE, CAREY DJ, ELMORE JR, TSAO PS, GRARUP N, JØRGENSEN T, WITTE DR, HANSEN T, PEDERSEN O, POLA R, GAETANI E, MAGNADOTTIR HB, WIJMENGA C, TROMP G, RONKAINEN A, RUIGROK YM, BLANKENSTEIJN JD, MUELLER T, WELLS PS, CORRAL J, SORIA JM, SOUTO JC, PEDEN JF, JALILZADEH S, MAYOSI BM, KEAVNEY B, STRAWBRIDGE RJ, SABATER-LLEAL M, GERTOW K, BALDASSARRE D, NYYSSÖNEN K, RAURAMAA R, SMIT AJ, MANNARINO E, GIRAL P, TREMOLI E, DE FAIRE U, HUMPHRIES SE, HAMSTEN A, HARALDSDOTTIR V, OLAFSSON I, MAGNUSSON MK, SAMANI NJ, LEVEY AI, MARKUS HS, KOSTULAS K, DICHGANS M, BERGER K, KUHLÉNBAÜMER G, RINGELSTEIN EB, STOLL M, SEEDORF U, ROTHWELL PM, POWELL JT, KUIVANIEMI H, ONUNDARSON PT,

VALDIMARSSON E, MATTHIASSEN SE, GUDBJARTSSON DF, THORGEIRSSON G, QUYYUMI AA, WATKINS H, FARRALL M, THORSTEINSDOTTIR U, STEFANSSON K. Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism.

J Am Coll Cardiol. 2012 Aug 21;60(8):722-9.

182. EMMERICH J, DUMARCET N, LORENCE A.

France's new framework for regulating off-label drug use. N Engl J Med. 2012 Oct 4;367(14):1279-81

183. MIRAULT T, EMMERICH J.

Maladie de Takayasu. Comment la prendre en charge ? Presse Med. 2012 Oct;41(10):975-85.

184. BÉRARD AM, BEDEL A, LE TREQUESSER R, FREYBURGER G, NURDEN A, COLOMER S, GUÉRIN V, VERGNES MC, BECKER F, CAMELOT G, BRESSOLETTE L, LACROIX P, CAMBOU JP, BURA-RIVIÈRE A, EMMERICH J, DARMON M, DELETRAZ AM, MESLI S, COLOMBIES B, VANBRUGGHE V, CONRI C, CONSTANS J. Novel risk factors for premature peripheral arterial occlusive disease in non-diabetic patients: a case-control study.

PLoS One. 2013;8(3):e37882. doi: 10.1371/journal.pone.0037882. Epub 2013 Mar 22.

185. SIMONE B, DE STEFANO V, LEONCINI E, ZACHO J, MARTINELLI I, EMMERICH J, ROSSI E, FOLSOM AR, ALMAWI WY, SCARABIN PY, DEN HEIJER M, CUSHMAN M, PENCO S, VAYA A, ANGCHAIKSUKSIRI P, OKUMUS G, GEMMATI D, CIMA S, AKAR N, OGUZULGEN KI, DUCROS V, LICHY C, FERNANDEZ-MIRANDA C, SZCZEKLIK A, NIETO JA, TORRES JD, LE CAM-DUCHEZ V, IVANOV P, CANTU-BRITO C, SHMELEVA VM, STEGNAR M, OGUNYEMI D, EID SS, NICOLOTTI N, DE FEO E, RICCIARDI W, BOCCIA S. Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetetrahydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. Eur J Epidemiol. 2013;28:621-47.

186. HOWANGYIN KY, LOINARD C, BAKKER W, GUERIN CL, VILAR J, D'AUDIGIER C, MAUGE L, BRUNEVAL P, EMMERICH J, LEVY B, POUYSSEGUR J, SMADJA DM, SILVESTRE JS. HIF-prolyl hydroxylase 2 inhibition enhances the efficiency of mesenchymal stem cells-based therapies for the treatment of critical limb ischemia. Stem Cells 2013 Sep 16. doi: 10.1002/stem.1540. [Epub ahead of print]

187. MARANINCHI D, EMMERICH J. L'éclosion de la thérapeutique en urologie. Progrès en urologie 2013 ;23 :1199-1200.

Projects

I participated as investigators or PI in several trials mainly concerning venous thrombosis and peripheral arterial disease.

Since May 2012 I am fully devoted to my job in the French Medical Agency (ANSM) and I have no implication in any other activity.

Memberships

Elected member of the nucleus of the working group on peripheral arterial disease from the European Society of Cardiology (ESC) (2009 - 2012).

Other Relevant Information